Dr. Howard A. Burris, III, on Modern Chemotherapy for Patients with HER2-Positive Breast Cancer
November 20th 2015Howard A. "Skip" Burris, III, MD, president, Clinical Operations, chief medical officer and executive director of Drug Development, Sarah Cannon, talks about chemotherapy in the era of personalized medicine.